Table 3.
Summary of HRs for number of +LNs stratified by change point of 5 +LNs for overall survival and disease-free survival and subdistributional HRs for locoregional recurrence and distant metastases
| HR/sHR | 95% CI | P value | |
|---|---|---|---|
|
| |||
| Overall survival | |||
| 0–5 +LNs | 1.21 | 1.1, 1.34 | <.001 |
| ≥6 +LNs | 1.02 | 1.01, 1.06 | <.001 |
| Disease-free survival | |||
| 0–5 +LNs | 1.19 | 1.08, 1.30 | <.001 |
| ≥6 +LNs | 1.04 | 1.02, 1.06 | <.001 |
| Locoregional recurrence | |||
| 0–5 +LNs | 1.28 | 1.10, 1.50 | <.001 |
| ≥6 +LNs | 1.00 | 0.96, 1.04 | .98 |
| Distant metastasis | |||
| 0–5 +LNs | 1.10 | 1.01, 1.20 | .028 |
| ≥6 +LNs | 1.05 | 1.02, 1.08 | .003 |
Abbreviations: CI = confidence interval; HR = hazard ratio (expressed as 1 unit increment); LN = lymph node; sHR = subdistributional HR.